Taking bacteriophage therapy seriously: A moral argument

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Verbeken, Gilbert ^a,b,c   Huys, Isabelle ^b   Pirnay, Jean Paul ^a   Jennes, Serge ^a   Chanishvili, Nina ^d   Scheres, Jacques ^e,f,g   Górski, Andrzej ^h,i   De Vos, Daniel ^a   Ceulemans, Carl ^c  

^a QUEEN ASTRID MILITARY HOSPITAL   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c ROYAL MILITARY ACADEMY   (Belgium)

^d George Eliava Institute of Bacteriophage Microbiology and Virology   (Georgia)

^e MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^f NATIONAL MEDICINES INSTITUTE   (Poland)

^g UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^h INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

ⁱ MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

PROBIOTIC AGENT; ANTIINFECTIVE AGENT;

ANTIMICROBIAL THERAPY; ARTICLE; BACTERIOPHAGE; BACTERIOPHAGE THERAPY; DRUG INDUSTRY; HEALTH CARE COST; HUMAN; MEDICAL ETHICS; MORALITY; NONHUMAN; RESPONSIBILITY; SOCIAL BEHAVIOR; SOCIAL WELFARE; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTIONS; BACTERIUM; BIOLOGICAL THERAPY; CHEMISTRY; EUROPE; TRENDS;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; BACTERIOPHAGES; BIOLOGICAL THERAPY; DRUG INDUSTRY; DRUG RESISTANCE, BACTERIAL; ETHICS, MEDICAL; EUROPE; HUMANS; MORALS;

EID: 84901260081     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/621316     Document Type: Article

References (48)

1. Cooper M. A., Shlaes D., Fix the antibiotics pipeline. Nature 2011 472 7341 32 2-s2.0-79953740494 10.1038/472032a
2. Kutateladze M., Adamia R., Bacteriophages as potential new therapeutics to replace or supplement antibiotics. Trends in Biotechnology 2010 28 12 591 595 2-s2.0-78149468115 10.1016/j.tibtech.2010.08.001
3. Bush K., Courvalin P., Dantas G., Tackling antibiotic resistance. Nature Reviews Microbiology 2011 9 12 894 896
4. Roberts R. R., Hota B., Ahmad L., Scott D., Foster S. D., Abbasi F., Schabowski S., Kampe L. M., Gr-Ciavarella G., Supino M., Naples J., Cordell R., Levy S. B., Weinstein R. A., Hospital and societal costs of antimicrobial- resistant infections in a chicago teaching hospital: implications for antibiotic stewardship. Clinical Infectious Diseases 2009 49 8 1175 1184 2-s2.0-70349895519 10.1086/605630
5. Wattal C., Oberoi J. K., Raveendran R., Prasad K. J., Current status of newer antiinfectives. Recent Patents on Anti-Infective Drug Discovery 2008 3 3 206 224 2-s2.0-58149176763
6. Fernebro J., Fighting bacterial infections-future treatment options. Drug Resistance Updates 2011 14 2 125 139 2-s2.0-79955755873 10.1016/j.drup.2011.02. 001
7. Maura D., Debarbieux L., Bacteriophages as twenty-first century antibacterial tools for food and medicine. Applied Microbiology and Biotechnology 2011 90 3 851 859 2-s2.0-79954671431 10.1007/s00253-011-3227-1
8. Levy S. B., Marshall B., Antibacterial resistance worldwide: causes, challenges and responses. Nature Medicine 2004 10 12 S122 S129 2-s2.0-10944272743 10.1038/nm1145 (Pubitemid 40018235)
9. Kumarasamy K. K., Toleman M. A., Walsh T. R., Bagaria J., Butt F., Balakrishnan R., Chaudhary U., Doumith M., Giske C. G., Irfan S., Krishnan P., Kumar A. V., Maharjan S., Mushtaq S., Noorie T., Paterson D. L., Pearson A., Perry C., Pike R., Rao B., Ray U., Sarma J. B., Sharma M., Sheridan E., Thirunarayan M. A., Turton J., Upadhyay S., Warner M., Welfare W., Livermore D. M., Woodford N., Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. The Lancet Infectious Diseases 2010 10 9 597 602 2-s2.0-77955917495 10.1016/S1473-3099(10)70143-2
10. Brzuszkiewicz E., Thürmer A., Schuldes J., Leimbach A., Liesegang H., Meyer F.-D., Boelter J., Petersen H., Gottschalk G., Daniel R., Genome sequence analyses of two isolates from the recent Escherichia coli outbreak in Germany reveal the emergence of a new pathotype: Entero-Aggregative-Haemorrhagic Escherichia coli (EAHEC). Archives of Microbiology 2011 193 12 883 891 2-s2.0-82355173436 10.1007/s00203-011-0725-6
11. Pirnay J.-P., De Vos D., Verbeken G., Merabishvili M., Chanishvili N., Vaneechoutte M., Zizi M., Laire G., Lavigne R., Huys I., Van Den Mooter G., Buckling A., Debarbieux L., Pouillot F., Azeredo J., Kutter E., Dublanchet A., Górski A., Adamia R., The phage therapy paradigm: prêt-à- porter or sur-mesure? Pharmaceutical Research 2011 28 4 934 937 2-s2.0-79955572725 10.1007/s11095-010-0313-5
12. Pirnay J.-P., Verbeken G., Rose T., Jennes S., Zizi M., Huys I., Lavigne R., Merabishvili M., Vaneechoutte M., Buckling A., De Vos D., Introducing yesterday's phage therapy in today's medicine. Future Virology 2012 7 4 379 390 2-s2.0-84859408710 10.2217/fvl.12.24
13. Meaden S., Koskella B., Exploring the risks of phage application in the environment. Frontiers in Microbiology 2013 4, article 358
14. Verbeken G., Pirnay J. P., De Vos D., Optimizing the European regulatory framework for sustainable bacteriophage therapy in human medicine. Archivum Immunologiae et Therapia Experimentalis 2012 60 3 161 172
15. Henein A., What are the limitations on the wider therapeutic use of phage? Bacteriophage 2013 3 2 e24872
16. Frank C., Werber D., Cramer J. P., Askar M., Faber M., An Der Heiden M., Bernard H., Fruth A., Prager R., Spode A., Wadl M., Zoufaly A., Jordan S., Kemper M. J., Follin P., Müller L., King L. A., Rosner B., Buchholz U., Stark K., Krause G., Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. The New England Journal of Medicine 2011 365 19 1771 1780 2-s2.0-80955168000 10.1056/NEJMoa1106483
17. Michael M., Elliott E. J., Ridley G. F., Hodson E. M., Craig J. C., Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura. Cochrane Database of Systematic Reviews 2009 1 CD003595 2-s2.0-62449258488
18. Maura D., Morello E., du Merle L., Bomme P., Le Bouguénec C., Debarbieux L., Intestinal colonization by enteroaggregative Escherichia coli supports long-term bacteriophage replication in mice. Environmental Microbiology 2012 14 8 1844 1854 2-s2.0-82155176993 10.1111/j.1462-2920.2011.02644.x
19. Merabishvili M., De Vos D., Verbeken G., Selection and characterization of a candidate therapeutic bacteriophage that lyses the Escherichia coli O104:H4 strain from the 2011 outbreak in Germany. PLoS One 2012 7 12 e52709
20. Brussow H., What is needed for phage therapy to become a reality in Western medicine? Virology 2012 434 2 138 142
21. Miȩdzybrodzki R., Borysowski J., Weber-Da̧browska B., Clinical aspects of phage therapy. Advances in Virus Research 2012 83 73 121 10.1016/B978-0-12-394438-2.00003-7
22. Huys I., Vaneechoutte M., Verbeken G., Debarbieux L., Key issues in phage therapy: a report of a dedicated workshop at the viruses of microbes II meeting. Research in Microbiology 2013 164 7 806 810
23. Miedzybrodzki R., Fortuna W., Weber-Dabrowska B., Górski A., Phage therapy of staphylococcal infections (including MRSA) may be less expensive than antibiotic treatment. Postepy Higieny i Medycyny Doświadczalnej 2007 61 461 465 2-s2.0-34548431799
24. Rice L. B., Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. Journal of Infectious Diseases 2008 197 8 1079 1081 2-s2.0-42549171131 10.1086/533452 (Pubitemid 351590040)
25. Munyaradzi M., Critical reflections on the principle of beneficence in biomedicine. The Pan African Medical Journal 2012 11, article 29
26. Kagan S., Normative Ethics 1998 Boulder, Colo, USA Westview Press
27. Miller R. B., Casuistry and Modern Ethics. A Poetics of Practical Reasoning 1996 London, UK University of Chicago Press
28. Kutter E., De Vos D., Gvasalia G., Alavidze Z., Gogokhia L., Kuhl S., Abedon S. T., Phage therapy in clinical practice: treatment of human infections. Current Pharmaceutical Biotechnology 2010 11 1 69 86 2-s2.0-77950166515 10.2174/138920110790725401
29. Khawaldeh A., Morales S., Dillon B., Alavidze Z., Ginn A. N., Thomas L., Chapman S. J., Dublanchet A., Smithyman A., Iredell J. R., Bacteriophage therapy for refractory Pseudomonas aeruginosa urinary tract infection. Journal of Medical Microbiology 2011 60 11 1697 1700 2-s2.0-80054724924 10.1099/jmm.0.029744-0
30. Chanishvili N., A Literature Review on the Practical Application of Bacteriophage Research 2012 Nova Science Publishers
31. Verbeken G., Pirnay J. P., Lavigne R., Call for a dedicated European legal framework for bacteriophage therapy. Archivum Immunologiae et Therapiae Experimentalis 2014 62 2 117 129
32. Loc-Carrillo C., Abedon S. T., Pros and cons of phage therapy. Bacteriophage 2011 1 2 111 114
33. Hoe S., Semler D. D., Goudie A. D., Respirable bacteriophages for the treatment of bacterial lung infections. Journal of Aerosol Medicine and Pulmonary Drug Delivery 2013 26 6 317 335 10.1089/jamp.2012.1001
34. Comeau A. M., Tétart F., Trojet S. N., Prère M.-F., Krisch H. M., Phage-antibiotic synergy (PAS): β -lactam and quinolone antibiotics stimulate virulent phage growth. PLoS One 2007 2 8, article e799 2-s2.0-40749128501 10.1371/journal.pone.0000799 (Pubitemid 351386577)
35. Kirby A. E., Synergistic action of gentamicin and bacteriophage in a continuous culture population of Staphylococcus aureus. PLoS One 2012 7 11 e51017
36. Declaration of Helsinki,. http://www.wma.net/en/30publications/ 10policies/b3/
37. Coppieters B., Fotion N., Moral Constraints on War. Principles and Cases 2008 2nd Lanham, Md, USA Lexington Books
38. http://www.mrsa-forum.com/products/index.asp?forumID=9270&subject= Phage-Therapy-Center-Saved-My-Life
39. Friedman M., The social responsibility of business is to increase its profit. New York Times Magazine 1970
40. Blasszauer B., Petty corruption in health care. Journal of Medical Ethics 1997 23 3 133 134 2-s2.0-0031157278
41. Pirnay J. P., Vanderkelen A., Ectors N., Beware of the commercialization of human cells and tissues: situation in the European Union. Cell Tissue Bank 2012 13 3 487 498
42. Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use, http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CONSLEG:2001L0083: 20110721:EN:PDF
43. Chanishvili N., A Literature Review of the Practical Application of Bacteriophage Research 2012 New York, NY, USA Nova Science Publishers
44. Abedon S. T., Kuhl S. J., Blasdel B. G., Kutter E. M., Phage treatment of human infections. Bacteriophage 2011 1 2 66 85
45. Kamm F. M., Intricate Ethics, Rights, Responsibilities, and Permissible Harm 2007 Oxford, UK Oxford University Press
46. Beauchamp T. L., Childress J. F., Principles of Biomedical Ethics 2009 New York, NY, USA Oxford University Press
47. Pirson M., Leclercq P., Jackson T., Leclercq M., Garrino M., Sion C., Financial consequences of hospital-acquired bacteraemia in three Belgian hospitals in 2003 and 2004. Journal of Hospital Infection 2008 68 1 9 16 2-s2.0-37749046128 10.1016/j.jhin.2007.10.006
48. Stevens H., van Overwalle G., van Looy B. E. J., Huys I., Perspectives and opportunities for precompetitive public-private partnerships in the biomedical sector. Biotechnology Law Report 2013 32 3 131 139